US 12,486,545 B2
Diagnostic and treatment of chronic pathologies such as Lyme disease
Hugues Gascan, Angers (FR); Marc Michaël Bransten, Vincennes (FR); Sylvie Chevalier, Angers (FR); and Hans Yssel, Paris (FR)
Assigned to Centre National de la Recherche Scientifique, Paris (FR); and Institut National de la Sante et de la Recherche Medicale, Paris (FR)
Appl. No. 16/647,231
Filed by Centre National de la Recherche Scientifique, Paris (FR); Institut National de la Santé et de la Recherche Médicale, Paris (FR); and Marc Michaël Bransten, Vincennes (FR)
PCT Filed Sep. 14, 2018, PCT No. PCT/EP2018/074835
§ 371(c)(1), (2) Date Mar. 13, 2020,
PCT Pub. No. WO2019/053175, PCT Pub. Date Mar. 21, 2019.
Claims priority of application No. 17306194 (EP), filed on Sep. 15, 2017.
Prior Publication US 2024/0182985 A1, Jun. 6, 2024
Int. Cl. C12Q 1/689 (2018.01); G01N 33/569 (2006.01); G16B 25/10 (2019.01)
CPC C12Q 1/689 (2013.01) [G01N 33/56911 (2013.01); G16B 25/10 (2019.02); C12Q 2600/158 (2013.01); G01N 2333/535 (2013.01); G01N 2333/57 (2013.01); G01N 2333/7155 (2013.01)] 5 Claims
 
1. A method for treating a late chronic form of Lyme disease in a subject, said method comprising steps of:
(A) verifying that the subject has a late chronic form of Lyme disease; and
(B) administering, to the subject, a treatment for late chronic form of Lyme disease comprising a therapeutically effective amount of an IL-RA therapeutic agent selected from the group consisting of IL-1α, IL-1β, anti-IL-1RA antibodies, and anti-IL-1RA interfering agents, wherein verifying that the subject has a late chronic form of Lyme disease comprises steps of:
(a) determining, in a biological sample obtained from said subject, an expression level of IL-1RA and an expression level of IFN-γ; and
(b) calculating a ratio [IL-1RA]/[IFN-γ] between the expression level of IL-1RA and the expression level of IFN-custom character determined in step (a); and
(c) comparing the ratio [IL-1RA]/[IFN-γ] calculated in step (b) with a ratio [IL-1RA]/[IFN-γ] determined using a biological sample obtained from a healthy subject or with a predetermined threshold ratio [IL-1RA]/[IFN-γ]0, wherein the healthy subject does not have a pathology or an infection,
wherein the ratio [IL-1RA]/[IFN-γ] calculated in step (b) that is higher than the ratio [IL-1RA]/[IFN-γ] determined for the healthy subject, or that is higher than the predetermined threshold ratio [IL-1RA]/[IFN-γ]0, is indicative of the late chronic chronic form of Lyme disease;
and/or comprises steps of:
(a′) determining, in a biological sample obtained from said subject, an expression level of IL-1RA and an expression level GM-CSF;
(b′) calculating a ratio [IL-1RA]/[GM-CSF] between the expression level of IL-1RA and the expression level of GM-CSF determined in step (a′); and
(c′) comparing the ratio [IL-1RA]/[GM-CSF] calculated in step (b′) with a ratio [IL-1RA]/[GM-CSF] determined using a biological sample obtained from a healthy subject or with a predetermined threshold [IL-1RA]/[GM-CSF]0, wherein the healthy subject does not have a pathology or an infection,
wherein the ratio [IL-1RA]/[GM-CSF] calculated in step (b′) that is higher than the ratio [IL-1RA]/[GM-CSF] determined for a healthy subject, or that is higher than the predetermined threshold ratio [IL-1RA]/[GM-CSF]0, is indicative of the late chronic form of Lyme disease.